All In Biotech

Drug Trial Radar · NCT04410965

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

May 20, 2020

Primary completion

Jul 12, 2021

Study completion Jul 12, 2021

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Evaluate the relationship between ABCG2 mutation (rs2231142) and teriflunomide exposure, during 6-month treatment with teriflunomide 14 mg Secondary Objective: Characterize the safety (AEs, such as ALT enhancement, hair thinning, diarrhea, nausea, etc.) during 6-month treatment with teriflunomide

Conditions

  • Multiple Sclerosis

Interventions

  • TERIFLUNOMIDEDrug

    Pharmaceutical form:tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK exposure: CmaxTime frame: From Week 8 to Week 24
  2. PK exposure: AUCtauTime frame: From Week 8 to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number

    China, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.